Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vivomixx
- Development stage
- Unknown
- Lead developer
- Mendes
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Vivomixx is a high-potency probiotic preparation containing the De Simone Formulation, a proprietary blend of eight specific strains of live bacteria: *Lactobacillus acidophilus*, *Lactobacillus plantarum*, *Lactobacillus paracasei*, *Lactobacillus delbrueckii* subsp. *bulgaricus*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Bifidobacterium infantis*, and *Streptococcus thermophilus*. It is designed to colonize the gastrointestinal tract and restore microbial balance, thereby improving intestinal barrier function and modulating inflammatory responses. Vivomixx is primarily used as a medical food or dietary supplement for the dietary management of gastrointestinal disorders, including ulcerative colitis, pouchitis, and irritable bowel syndrome (IBS). In clinical research, it is being evaluated for its potential to improve vitamin status and metabolic markers in patients with celiac disease who remain symptomatic or have nutrient deficiencies despite following a strict gluten-free diet.
- Brand names
- VivomixxVisbiome
- Other names
- De Simone FormulationDSF
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on Vivomixx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivomixx.